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ABSTRACT
Objective: To evaluate changes in residual platelet
reactivity (RPR) over time, and bleeding and ischaemic
events rate using 5 vs 10 mg maintenance dose (MD)
regimens of prasugrel 1 month after acute coronary
syndrome (ACS).
Background: The optimal level of RPR with prasugrel
may change over time after an ACS.
Methods: After 60 mg loading dose of prasugrel (T0)
followed by 10 mg/day for 1 month, patients were
randomised to receive prasugrel 10 mg/day (n=95,
group A) or 5 mg/day MD (n=98, group B) up to
1 year. RPR was assessed at T0, 37 (T1) and 180 days
(T2). The primary end point was Bleeding Academic
Research Consortium (BARC) bleeding events ≥2
between 1 and 12 months, and the secondary
composite end point was cardiac death, myocardial
infarction, stroke and definite/probable stent
thrombosis.
Results: From T0 to T1, RPR significantly increased
in both groups A and B and the increase was higher
for group B (δ ADP 10 µmol: 13.8%±14.7% vs
23.5%±19.2%, p=0.001). At T2 a lower rate of high
RPR patients were found in group A (2.6% vs13.3%;
p=0.014). The BARC type ≥2 bleeding occurred in
12.6% of group A versus 4.1% of group B (OR 0.29,
95% CI 0.09 to 0.94) and secondary end point in 2.1%
vs 1.0% (p=0.542), respectively, without stent
thrombosis.
Conclusions: RPR increases shifting from 60 mg
loading dose to 10 mg/day prasugrel MD with a further
increase of RPR reducing prasugrel MD to 5 mg
1 month after ACS. Clinical value of these
pharmacodynamic findings should be proved in larger
clinical trials.
Trial registration number: NCT01790854.
INTRODUCTION
The Trial to Assess Improvement in
Therapeutic Outcomes by Optimizing Platelet
Inhibition with Prasugrel–Thrombolysis in
Myocardial Infarction (TRITON–TIMI-38)
study showed that in patients with acute cor-
onary syndrome (ACS) undergoing percutan-
eous coronary intervention (PCI) the use of
prasugrel translated into reduced ischaemic
event rate but it was also associated with
increased major bleeding rate compared with
clopidogrel.1 Furthermore, the Food and
Drug Administration (FDA) review of
TRITON study2 highlighted that the risk–
benefit appears to be greatest early in therapy
with prasugrel, with fewer end points pre-
vented per bleed as therapy is continued. In
addition, the increase of residual platelet
reactivity (RPR) after early period of ACS3 4
and the association between bleeding events
and low RPR are well known.5Thus, the
optimal level of platelet inhibition with prasu-
grel may change over time after an ACS.
Therefore, switching from prasugrel 10 mg/
day maintenance dose (MD) to 5 mg/day MD
1 month after the index event may be consid-
ered as able to reduce bleeding events. We
sought to evaluate RPR change over time and
the occurrence of bleeding and ischaemic
events using reduced MD of prasugrel (5 vs
10 mg) in patients with ACS 1 month after
drug-eluting stent (DES) implantation.
KEY QUESTIONS
What is already known about this subject?
▸ Prasugrel 10 mg/day maintenance dose is
recommended for 1 year in patients with acute
coronary syndrome (ACS) treated with
drug-eluting stent.
What does this study add?
▸ Physicians should carefully evaluate patient’s
ischaemic and bleeding risks in determining
which prasugrel maintenance dose might be
more efficacious.
How might this impact on clinical practice?
▸ The pharmacodynamic findings of Bleeding
Events and Maintenance Dose of Prasugrel
(BLESS) study might provide an important basis
for the robust design of future trials focused on
the optimisation of level of platelet inhibition
in ACS.
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MATERIALS AND METHODS
The Bleeding Events and Maintenance Dose of
Prasugrel (BLESS) trial was an open-label, randomised,
single-centre study, designed to evaluate whether 1
month after PCI for ACS the shifting of prasugrel MD
from 10 mg to 5 mg/day may reduce bleeding events.
For this purpose, all patients with ACS underwent
second-generation or third-generation DES implantation
and received 60 mg loading dose (T0) of prasugrel fol-
lowed by 10 mg/day for 1 month. Thereafter, patients
confirmed to be adherent to prasugrel therapy were ran-
domised to receive prasugrel 10 mg/day (group A) or
5 mg/day MD (group B) up to 1 year. All patients
received 325 mg of aspirin followed by 100 mg/day for
at least 1 year. RPR was assessed by light transmittance
aggregometry at T0, 37 (T1, 7 days after the randomisa-
tion at 10 or 5 mg of prasugrel) and 180 days (T2).6 The
inclusion criteria were all patients with ACS (≤75 years)
treated with PCI and dual antiplatelet therapy (aspirin
plus prasugrel) at the Division of Cardiology of Careggi
Hospital, Florence, Italy, and informed written consent.
ACS included unstable angina with ST segment changes,
non-ST segment elevation acute myocardial infarction
(MI) and ST segment elevation acute MI.6 Full exclusion
criteria included age <18 years, active bleeding, bleeding
diathesis, coagulopathy; history of gastrointestinal or
genitourinary bleeding <2 months; major surgery in the
past 6 weeks; history of intracranial bleeding or struc-
tural abnormalities; suspected aortic dissection; any pre-
vious transient ischaemic attack/stroke; administration
in the week before the index event of ticlopidine, clopi-
dogrel, prasugrel, ticagrelor, thrombolytics, bivalirudin,
low molecular weight heparin or fondaparinux; known
relevant haematological deviations: haemoglobin <10 g/
dL, thrombocytopaenia <100×109/L; use of Coumadin
derivatives within the past 7 days; chronic therapy with
prasugrel or ticagrelor; known malignancies or other
comorbid conditions with life expectancy <1 year;
known severe liver disease, severe renal failure; known
allergy to the study medications; pregnancy. The study
was supported by the investigators (ClinicalTrial.gov
identifier: NCT01790854). The protocol was approved
by local investigational review boards and performed in
compliance with good clinical practice and the
Declaration of Helsinki. All patients provided signed
informed consent prior to any study procedure.
The safety primary end point was the occurrence of
bleeding type ≥2 events according to the Bleeding
Academic Research Consortium (BARC) criteria,7
during the randomised treatment period (from 1 to
12 months). The secondary composite exploratory end
point was cardiac death, MI or stroke.6 Other secondary
end points of the study were: (1) the occurrence of def-
inite or probable stent thrombosis from 1 to 12 months
(the angiographic follow-up was strongly encouraged);8
(2) the pharmacodynamic response in patients with
MD prasugrel 10 mg/day compared with those who
were randomised to MD prasugrel 5 mg/day; and
(3) the incidence of high RPR patients defined as ADP
10 µmol ≥70%.
In-hospital adverse events were recorded before dis-
charge. One-month, 6-month and 12-month clinical
follow-up data were obtained in outpatient consultation.
Adverse clinical events were independently adjudicated
by an external clinical event committee whose members
were unaware of the group assignments. All source docu-
ments concerning events were provided to the clinical
event committee, for accuracy and completeness.
Discrete data were summarised as frequencies,
whereas continuous data as mean±SD or median. The
χ2 test or Fisher’s exact test were used for comparison of
categorical variables, and the unpaired two-tailed
Student’s t-test or Kolmogorov-Smirnov non-parametric
test were used to test differences among continuous vari-
ables for the end point. Odds risk (OR) and 95% CI
were calculated. The time course of changes of RPR
between and within groups was made by analysis of vari-
ance (ANOVA). BARC bleeding event-free survival was
estimated by the Kaplan-Meier method. The log-rank
test was used to compare BARC type ≥2 bleeding
between patients treated with prasugrel 5 mg/day MD
and patients treated with prasugrel 10 mg/day MD. All
tests were two-sided and a p<0.05 was considered signifi-
cant. All analyses were performed using the software
package SPSS V.19.0 (SPSS, Chicago, Illinois, USA).
The study was designed on the basis of the superiority
principle. We hypothesised that the primary safety end
point (BARC type ≥2) would be 8% for 5 mg prasugrel
MD and 16% for 10 mg prasugrel MD, which corre-
sponds to a 50% bleeding reduction with 5 mg MD of
prasugrel. The planned enrolment of 450 patients with
ACS (225 patients in arm 5 mg/day MD; 225 patients in
arm 10 mg/day MD) provides 80% power for detecting
this bleeding reduction at α-level of 0.05. However, since
the interim analysis, planned 2-year after the start of the
study, showed fewer than expected events, after a discus-
sion within the steering committee, we decided to stop
the study considering the need of a larger simple size
and a longer enrolment period to achieve the objective
of the BLESS study, other than a reduced resource
available.
RESULTS
Owing to fewer than expected events, the trial was pre-
maturely stopped after enrolling 193 of 450 planned
patients. Thus, between November 2012 and April 2014,
a total of 193 patients were enrolled in the BLESS study
(study flow, figure 1): 95 patients randomised to prasu-
grel MD 10 mg/day (group A) and 98 to prasugrel MD
5 mg/day (group B). Baseline clinical characteristics of
two arm patients were well matched (see table 1). The
incidence of diabetes, female gender, chronic renal
failure, previous PCI and coronary artery bypass graft
and reduced left ventricular ejection fraction were not
different between two group patients. Overall, 29%
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presented with acute MI. Moreover, 61% of patients
showed multivessel coronary artery disease and 15% left
main disease (table 2). All patients underwent PCI using
second-generation and third-generation DES, with a
mean of 1.5±0.7 vessel treated, and with a mean stent
length of 31±21 mm. At hospital discharge, the medical
therapy prescribed was similar between groups. The
online supplementary table S1 shows the outcome
before randomisation period.
Out of 193 patients, RPR was assessed in 152, since 41
patients receiving IIb/IIIa inhibitors during the PCI pro-
cedures were excluded. The RPR at T0 were similar
between group A and B (ADP 10 µmol: 34.5±16.2 vs 31.5
±17.2; p=0.697, respectively). Out of 152, 2 (1.3%) high
RPR patients were found. From T0 to T1, the RPR sig-
nificantly increased in group A as well as in group B and
the increase was higher for group B (δ ADP 10 µmol:
13.8%±14.7% vs 23.5%±19.2%, p=0.005), but from T1 to
T2 no further increase of RPR was found in both groups
(see ANOVA in figure 2 and online supplementary table
S2). At T2 a lower rate of high RPR patients were found
in group A compared with the group B (2.6% vs13.3%;
p=0.014; table 2).
BARC bleedings were observed in 47.3% and 31.6% of
group A and B (p=0.025); the BARC type 1 or 2 bleed-
ing occurred in 45.3% vs 29.6% (p=0.024), the BARC
type 2 in 10.5% and 2% (p=0.014), the BARC type 3a in
2.1% vs 2.0% (p=0.974), and the BARC type 2 or 3a in
Figure 1 BLESS trial flow chart.
ACS, acute coronary syndrome;
BLESS, Bleeding Events and
Maintenance Dose of Prasugrel;
PCI, percutaneous coronary
intervention.
Table 1 Baseline characteristics and clinical presentation at hospital admission of study population
Variables
Group A (10/10)
(n=95)
Group B (10/5)
(n=98) All (n=193) p Value
Age, years 62.2±10.0 62.2±10.2 62.2±10.1 0.992
Female gender 13 (13.7) 14 (14.3) 27 (14.0) 0.904
Body mass index, kg/m2 27.5±3.3 27.2±3.6 27.3±3.4 0.505
Body mass index ≥30 26 (27.4) 20 (20.4) 46 (23.8) 0.311
Diabetes mellitus 29 (30.5) 21 (21.4) 50 (25.9) 0.149
Hyperlipidaemia 48 (50.5) 43 (43.9) 91 (47.2) 0.355
Smoker 29 (30.5) 39 (39.8) 68 (35.2) 0.178
Hypertension 55 (57.9) 56 (57.1) 111 (57.5) 0.916
Previous MI 24 (25.3) 17 (17.3) 41 (21.2) 0.179
Previous PCI 32 (33.7) 28 (28.6) 60 (31.1) 0.443
Previous CABG 5 (5.3) 3 (3.1) 8 (4.1) 0.443
Chronic renal failure 8 (8.6) 4 (4.1) 12 (6.3) 0.205
LV ejection fraction (%) 51.8±9.0 52.8±9.4 52.3±9.2 0.429
LV ejection fraction ≤40% 12 (12.6) 12 (12.2) 24 (12.4) 0.935
STEMI 29 (30.5) 27 (27.6) 56 (29.0) 0.649
Values are expressed as mean±SD or n (%).
MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; LV, left ventricular; STEMI,
ST-elevation myocardial infarction.
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12.6% and 4.1% (OR 0.29, 95% CI 0.09 to 0.94;
p=0.031), respectively (see table 3). No BARC type 4 or
5 bleeding occurred. Event-free survival from BARC type
≥2 bleeding during randomisation period is shown in
figure 3. Freedom from BARC type ≥2 bleeding events
was higher in 5 mg/day prasugrel MD arm in compari-
son with 10 mg/day prasugrel MD arm (log-rank test,
p=0.030).
The secondary composite exploratory end point
occurred in 2.1% of group A (one MI, one stroke) versus
1.0% of group B (one MI), p=0.542 (see table 3).
Considering the balance of safety and efficacy end point,
the net clinical benefit was in favour of group B: 14.7% vs
5.1% (OR0.31, 95% CI 0.10 to 0.90, p=0.024). Urgent
target vessel revascularisation rate was very low in both
groups: 1 (1.1%) in group A versus 0 (0%) in group B
(p=0.309). No definite or probable stent thrombosis
occurred in both groups (clinical follow-up rate 100%,
6-month angiographic follow-up rate 83.9% (162/193)).
During the randomisation period, two patients, both in
group A, discontinued prasugrel: a gastric bleeding
occurred at 6 months in the first patient and a haemor-
rhagic stroke occurred at 7 months in the second.
DISCUSSION
A 5 mg/day prasugrel MD was used in the Targeted
Platelet Inhibition to Clarify the Optimal Strategy to
Table 2 Angiographic, procedural characteristics and discharge therapy of study population
Variables
Group A (10/10)
(n=95)
Group B (10/5)
(n=98) All (n=193) p Value
Angiographic characteristics
Multivessel coronary disease 61 (64.2) 57 (58.2) 118 (61.1) 0.389
Three-vessel coronary disease 30 (31.6) 25 (25.5) 55 (28.5) 0.350
Left main disease 14 (14.7) 15 (15.3) 29 (15.0) 0.912
Procedural characteristics
Number of treated vessels 1.5±0.7 1.5±0.7 1.5±0.7 0.798
Total stent length, mm 49.0±35.7 41.4±29.7 45.2±33.0 0.107
Stent length per culprit vessel, mm 33.4±23.6 28.7±18.0 31.0±21.0 0.118
Number of stents per patient 2.3±1.3 2.0±1.2 2.2±1.3 0.145
Number of stents per culprit vessel 1.6±0.8 1.4±0.7 1.5±0.8 0.179
Multivessel PCI 39 (41.1) 38 (38.8) 77 (39.9) 0.747
DES 95 (100) 98 (100) 193 (100) –
Second-generation DES 72 (75.8) 70 (71.4) 142 (73.5) 0.492
Everolimus Eluting Stent (Xience) 65 (90.3) 59 (85.5) 124 (87.9) 0.233
Everolimus Eluting Platinum Chromium Stent (Promus
Element Plus)
6 (8.3) 9 (13.0) 15 (10.6) 0.365
Zotarolimus Eluting Stent (Resolute Integrity) 1 (1.4) 2 (2.9) 3 (2.1) 0.535
Third-generation DES 23 (24.2) 28 (28.6) 51 (26.4) 0.492
Biodegradable polymer biolimus-eluting stent (Nobori) 10 (43.5) 9 (32.1) 19 (37.3) 0.405
BioFreedom Polymer-Free (Cre8) 13 (56.5) 19 (67.9) 32 (62.7) 0.405
GP inhibitors IIb/IIIa 18 (18.9) 23(23.5) 41 (21%) 0.442
Discharge therapy
Aspirin 95 (100) 98 (100) 193 (100) –
Statins 92 (96.8) 92 (93.9) 184 (95.3) 0.329
ACE inhibitors or ARBs 67 (70.5) 78 (79.6) 145 (75.1) 0.145
β-blockers 70 (73.7) 60 (61.2) 130 (67.4) 0.065
Proton pump inhibitors 78 (82.1) 71 (72.4) 149 (77.2) 0.110
Hospital length of stay, day 3.4±2.0 3.7±5.9 3.5±4.4 0.544
Values are expressed as mean±SD or n (%).
ARBs, angiotensin receptor blockers; DES, drug-eluting stent; GP, glycoprotein; PCI, percutaneous coronary intervention.
Figure 2 Time course and magnitude of changes of RPR
within group B prasugrel 10/5 mg/day (─○─) and group A
prasugrel 10/10 mg/day (─□─) and between groups. RPR,
residual platelet reactivity.
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Medically Manage Acute Coronary Syndromes
(TRILOGY ACS) trial9 to reduce bleeding complications
in the vulnerable groups of elderly (>75 years) patients
and younger, low body weight patients (<60 kg). RPR
values of these patients using prasugrel MD 5 mg/day
was non-inferior to prasugrel MD 10 mg/day used in
younger, heavier patients.10 11 Moreover, the antiplatelet
effects of the prasugrel MD 5 mg/day were greater than
the effects with clopidogrel. These pharmacodynamic
findings were confirmed in the larger TRILOGY platelet
function substudy.12 Direct pharmacodynamic data to
support the potential use of prasugrel MD 5 mg/day to
reduce bleeding risk without an increase in the ischae-
mic risk in patients with ACS (≤75 years old) 1 month
after 60 mg prasugrel loading dose (LD) for PCI are
lacking. In the present study, we reported that the RPR
increases between loading dose and 1 month, and an
excess of RPR was found after shifting prasugrel MD
from 10 to 5 mg/day. The concentration of active metab-
olite produced after 60 mg LD of prasugrel is higher
(booster effect) in comparison to the one produced
after 10 mg/day MD of prasugrel, explaining the change
of RPR observed from T0 to T1 in this ACS population.
In the present study, from T1 to T2 after ACS a trend
towards a not significant reduction of RPR was observed,
likely due to the spontaneous decrement of platelet
reactivity. Thus, the combination of the lower produc-
tion of active metabolite associated with MD prasugrel
(favouring 5 vs 10 mg/day) and the spontaneous decre-
ment of platelet reactivity after ACS may potentially
explain the pattern of change of RPR observed in these
patients. In addition, in the early phase of ACS, RPR
values are influenced by several confounding factors, in
particular by thrombus formation, the inflammation, the
shear stress, the use of statin and other unknown vari-
ables. All these factors progressively either reduce their
influence or disappear at 1 month.3 13 High on treat-
ment RPR is well defined for clopidogrel and has been
clearly identified as a risk marker for ischaemic events.14
High on treatment RPR can also exist with prasugrel in
ACS after a LD of 60 mg and to a lower extent (<6% of
treated patient) on the MD of 10 mg.15 Recent rando-
mised trials as well as registry designed to evaluate
whether more intensive antiplatelet therapy in acute
Table 3 Clinical outcomes during randomisation period (from 1 to 12 months)
Variables
Group A
10/10
(n=95)
Group B
10/5
(n=98) All (n=193) OR 95% CI p Value
Primary safety end points
BARC
Any bleeding 45 (47.3) 31 (31.6) 76 (39) 0.51 0.28 to 0.92 0.025
Type 1 33 (34.7) 27 (27.5) 60 (31.0) 0.71 0.39 to 1.31 0.280
Type 2 10 (10.5) 2 (2.0) 12 (6.2) 0.17 0.03 to 0.83 0.014
Type 1 and 2 43 (45.3) 29 (29.6) 72 (37.3) 0.51 0.28 to 0.91 0.024
Type 3
Type 3a 2 (2.1) 2 (2.0) 4 (2.0) 0.96 0.13 to 7.02 0.974
Type 3b 0 (0) 0 (0) 0 (0) – – –
Type 3c 0 (0) 0 (0) 0 (0) – – –
Type 2 and 3 12 (12.6) 4 (4.1) 16 (8.2) 0.29 0.09 to 0.94 0.031
Type 4 0 (0) 0 (0) 0 (0) – – –
Type 5
Type 5a 0 (0) 0 (0) 0 (0) – – –
Type 5b 0 (0) 0 (0) 0 (0) – – –
Secondary efficacy composite end points
MACE 2 (2.1) 1 (1.0) 3 (1.6) 0.542
Cardiac death 0 (0) 0 (0) 0 (0) –
Myocardial infarction 1 (1.1) 1 (1.0) 2 (1.0) 0.982
TIA or stroke 1 (1.1) 0 (0) 1 (0.5) 0.309
Other secondary end points
Definite/probable stent thrombosis 0 (0) 0 (0) 0 (0) – – –
Prasugrel discontinuation* 2 (2.1) 0 (0) 2 (1.0) 0.149
Non cardiac death† 1 (1.1) 0 (0) 1 (0.5) 0.309
Urgent TVR 1 (1.1) 0 (0) 1 (0.5) 0.309
Angiographic sixth month follow-up 83 (87.4) 79 (80.6) 162 (83.9) 0.201
Definite stent thrombosis 0 (0) 0 (0) 0 (0) – – –
Restenosis 13 (15.7) 8 (10.1) 21 (13.0) 0.294
Values are expressed as mean±SD or n (%).
*Gastric bleeding at 6 months and haemorrhagic stroke at 7 months.
†Creutzfeldt-Jakob disease.
BARC, Bleeding Academic Research Consortium; MACE, major adverse cardiovascular event; TIA, transient ischaemic attack; TVR, target
vessel revascularisation.
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phase, using high-dose clopidogrel16 6 or prasugrel,17 18
might improve clinical outcome failed to show the
benefit of this strategy. Differently, the present study was
designed to evaluate the possibility to optimise the level
of platelet inhibition obtained with prasugrel after the
acute phase of ACS, focusing on the concept that the
optimal level of platelet inhibition may change overtime.
The adoption of the strategy reducing the MD of pra-
sugrel from 10 to 5 mg/day might be able to optimise
the risk/benefit profile of prasugrel in patients with ACS
1 month after second-generation or third-generation
DES implantation. In fact, a 49% risk reduction in any
BARC bleedings is associated with this strategy.
Specifically, in the present study the most common
bleedings are BARC type 1. However, nuisance-bleeding
type 1 occurrence seems to be not significantly influ-
enced by a reduced prasugrel MD strategy. On the con-
trary, an 83% risk reduction in BARC type 2 bleedings
and, yet, a 71% risk reduction in BARC≥2 were asso-
ciated with reduced prasugrel MD strategy. These find-
ings are not negligible, since the occurrence of BARC
type 2 bleedings, even minor, may be clinically relevant
hurting the patient’s day life and potentially reducing
patient adherence to treatment with new antiplatelet
agents such as prasugrel, favouring its disruption with
potential consequences on ischaemic events.19 In fact, in
the present study no discontinuation of prasugrel MD
5 mg was observed. Conversely, two patients taking
10 mg MD discontinued prasugrel.19 Finally, in the
BLESS study the BARC≥2 bleeding event curves begin
to separate soon after the randomisation period and
continue to diverge throughout the follow-up favouring
prasugrel MD 5 mg/day (figure 3), in keeping with pre-
vious and recent observations.20 21
Regarding the secondary exploratory efficacy end
points we did not observe any increase in thrombotic
events using prasugrel MD 5 mg/day. Surprisingly, we
observed an impressive ‘0’ rate of definite or probable
stent thromboses in the BLESS study population.
Compared with bare metal stent and first-generation
DES, the risk of definite or probable stent thrombosis is
an average 50% lower with new generation DES.22 23 A
significant reduction of stent thrombosis was observed in
the TRITON1 and in the Platelet Inhibition and Patient
Outcomes (PLATO)24 studies using first-generation DES
in only 40% and 19% of cases, respectively. It is conceiv-
able that our study benefited from the use of second-
generation and third-generation DES. These devices
were recently shown to be superior to the first-
generation DES for revascularisation and clinical out-
comes.25 This may be due to the fact that new gener-
ation DES with thin stent struts, advanced/absent
polymers and improved antiproliferation agents along
with better implantation techniques available, promote
an early healing of stent struts favouring a near ‘0’ stent
thrombosis. Finally, one should realise that in the early
phase of an ACS, it is important to obtain and maintain
an effective level of platelet inhibition. One month after
an ACS, the optimal level of platelet inhibition may
change and the adoption of a tailored strategy, using a
reduced MD of prasugrel, might optimise the risk/
benefit profile of prasugrel providing slightly less, but
still consistent, platelet inhibition that translate into
reducing bleeding risk without increasing the risk of
thrombotic events. Of course, we recognise that no
definitive conclusions can be drawn from the BLESS
study; however, these findings can add some insights
into the body of evidence of the dual antiplatelet
therapy in ACS patient and may help us to customise the
dual antiplatelet therapy according to the type of stent
implanted in a patient with ACS.21 26
The BLESS study was prematurely interrupted result-
ing in the enrolment in a population underpowered for
clinical events. Accordingly, the observed 71% risk
reduction of BARC type ≥2 bleeding without any appar-
ent increase of thrombotic events may be an overesti-
mation of the magnitude of benefit and may be
considered only as a hypothesis-generating finding.
Moreover, whether the treatment benefit observed may
be generalisable to non-thienopyridine P2Y12 inhibitor
or other stent types24 27 28 is unknown. Despite these
limitations, the pharmacodynamic findings associated
with this strategy in current PCI patients have never
been described and might provide an important basis
for the robust design of future trials focused on the
optimisation of level of platelet inhibition in patients
with ACS.
CONCLUSIONS
The BLESS trial shows that in patients with ACS the RPR
increases shifting from 60 mg loading dose to 10 mg/
Figure 3 BARC type ≥2 bleeding-free survival according to
the treatment with 5 mg/day prasugrel MD group B (─), or
10 mg/day prasugrel MD group A (─). Event rates were
compared by log-rank test. BARC, Bleeding Academic
Research Consortium; MD, maintenance dose.
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day prasugrel MD. A further increase in RPR and a
higher rate of high RPR patients was observed shifting
from 10 to 5 mg/day prasugrel MD after 1 month.
Whether the adoption of this tailored strategy using a
reduced MD of prasugrel might optimise the risk/
benefit profile of this high-potency antiplatelet drug
should be proved in larger clinical trials.
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